InvestorsHub Logo
Followers 15
Posts 151
Boards Moderated 0
Alias Born 06/20/2020

Re: None

Tuesday, 01/26/2021 8:32:20 AM

Tuesday, January 26, 2021 8:32:20 AM

Post# of 146
Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

Silo Pharma, Inc.

Tue, January 26, 2021, 8:18 AM·2 min read

Englewood Cliffs, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, announced today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.


https://finance.yahoo.com/news/silo-pharma-reaches-terms-university-131800548.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SILO News